Levothyroxine Sodium Patent Expiration
Levothyroxine Sodium was first introduced by Jerome Stevens Pharmaceuticals Inc
Levothyroxine Sodium Patents
Given below is the list of patents protecting Levothyroxine Sodium, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Tirosint-sol | US11241382 | Administration regimen of compositions of T4 thyroid hormone with high oral absorption | Sep 17, 2039 | Ibsa |
| Levolet | US10231931 | Thyroid hormone oral dosage forms and methods of using the same | Mar 23, 2038 | Genus Lifesciences |
| Levolet | US10406108 | Thyroid hormone oral dosage forms and methods of using the same | Mar 23, 2038 | Genus Lifesciences |
| Tirosint-sol | US10537538 | High-stability packaged solutions of T4 thyroid hormone | Feb 28, 2037 | Ibsa |
| Tirosint-sol | US11096913 | High-stability packaged solutions of T4 thyroid hormone | Feb 28, 2037 | Ibsa |
| Levothyroxine Sodium | US10398669 | Levothyroxine liquid formulations | Dec 01, 2036 | Fresenius Kabi Usa |
| Levothyroxine Sodium | US11135190 | Levothyroxine liquid formulations | Dec 01, 2036 | Fresenius Kabi Usa |
| Levothyroxine Sodium | US9782376 | Levothyroxine liquid formulations | Dec 01, 2036 | Fresenius Kabi Usa |
| Levothyroxine Sodium | US11154498 | Stabilized liquid formulation of levothyroxine | Jul 20, 2036 | Hikma |
| Ermeza | US9345772 | Liquid levothyroxine formulations | Feb 27, 2035 | Mylan |
| Levothyroxine Sodium | US9006289 | Levothyroxine formulations | Oct 03, 2032 | Fresenius Kabi Usa |
| Levothyroxine Sodium | US9168238 | Levothyroxine formulations | Aug 29, 2032 | Fresenius Kabi Usa |
| Levothyroxine Sodium | US9168239 | Levothyroxine formulations | Aug 29, 2032 | Fresenius Kabi Usa |
| Thyquidity | US9050307 | Method for the preparation of a levothyroxine solution | Aug 06, 2031 | Azurity |
| Tirosint | US7691411 | Pharmaceutical formulae for thyroid hormones and procedures for obtaining them |
Mar 14, 2024
(Expired) | Ibsa |
| Tirosint | US7723390 | Pharmaceutical formulations for thyroid hormones |
Mar 14, 2024
(Expired) | Ibsa |
| Tirosint | US7723390 | Pharmaceutical formulations for thyroid hormones |
Mar 14, 2024
(Expired) | Inst Biochimique |
| Levoxyl | US7101569 | Methods of administering levothyroxine pharmaceutical compositions |
Oct 02, 2023
(Expired) | King Pharms |
| Levoxyl | US6555581 | Levothyroxine compositions and methods |
Feb 15, 2022
(Expired) | King Pharms |
| Levoxyl | US7067148 | Stabilized pharmaceutical and thyroid hormone compositions and method of preparation |
Feb 15, 2022
(Expired) | King Pharms |
| Levo-t | US6399101 | Stable thyroid hormone preparations and method of making same |
Mar 30, 2020
(Expired) | Cediprof Inc |
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Levothyroxine Sodium's patents.
Latest Legal Activities on Levothyroxine Sodium's Patents
Given below is the list recent legal activities going on the following patents of Levothyroxine Sodium.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 4th Year, Large Entity | 20 Jun, 2023 | US10537538 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 27 Apr, 2023 | US9168238 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 27 Apr, 2023 | US9168239 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 03 Mar, 2023 | US10398669 |
| Payment of Maintenance Fee, 8th Yr, Small Entity | 07 Dec, 2022 | US9050307 |
| Change in Power of Attorney (May Include Associate POA) Critical | 01 Dec, 2022 | US9168238 |
| Email Notification Critical | 01 Dec, 2022 | US9168239 |
| Change in Power of Attorney (May Include Associate POA) Critical | 01 Dec, 2022 | US9168239 |
| Email Notification Critical | 01 Dec, 2022 | US9168238 |
| Correspondence Address Change Critical | 21 Nov, 2022 | US9168238 |
Levothyroxine Sodium's Family Patents
Explore Our Curated Drug Screens
Levothyroxine Sodium Generic API Manufacturers
Several generic applications have been filed for Levothyroxine Sodium. The first generic version for Levothyroxine Sodium was by Mylan Pharmaceuticals Inc and was approved on Jun 5, 2002. And the latest generic version is by Xiromed Pharma Espana Sl and was approved on Nov 29, 2024.
Given below is the list of companies who have filed for Levothyroxine Sodium generic, along with the locations of their manufacturing plants worldwide.
1. ACCORD HLTHCARE
Accord Healthcare Inc has filed for 12 different strengths of generic version for Levothyroxine Sodium. Given below are the details of the strengths of this generic introduced by Accord Hlthcare.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 0.125MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | tablet | Prescription | ORAL | AB1,AB2,AB3,AB4 | Oct 19, 2020 |
| 0.112MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | tablet | Prescription | ORAL | AB1,AB2,AB3,AB4 | Oct 19, 2020 |
| 0.137MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | tablet | Prescription | ORAL | AB1,AB2,AB3,AB4 | Oct 19, 2020 |
| 0.2MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | tablet | Prescription | ORAL | AB1,AB2,AB3,AB4 | Oct 19, 2020 |
| 0.175MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | tablet | Prescription | ORAL | AB1,AB2,AB3,AB4 | Oct 19, 2020 |
| 0.3MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | tablet | Prescription | ORAL | AB1,AB2,AB3,AB4 | Oct 19, 2020 |
| 0.15MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | tablet | Prescription | ORAL | AB1,AB2,AB3,AB4 | Oct 19, 2020 |
| 0.025MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | tablet | Prescription | ORAL | AB1,AB2,AB3,AB4 | Oct 19, 2020 |
| 0.05MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | tablet | Prescription | ORAL | AB1,AB2,AB3,AB4 | Oct 19, 2020 |
| 0.075MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | tablet | Prescription | ORAL | AB1,AB2,AB3,AB4 | Oct 19, 2020 |
| 0.088MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | tablet | Prescription | ORAL | AB1,AB2,AB3,AB4 | Oct 19, 2020 |
| 0.1MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | tablet | Prescription | ORAL | AB1,AB2,AB3,AB4 | Oct 19, 2020 |
2. AMNEAL
Amneal Pharmaceuticals Llc has filed for 12 different strengths of generic version for Levothyroxine Sodium. Given below are the details of the strengths of this generic introduced by Amneal.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 0.125MG | tablet | Discontinued | ORAL | N/A | Feb 19, 2019 |
| 0.137MG | tablet | Discontinued | ORAL | N/A | Feb 19, 2019 |
| 0.15MG | tablet | Discontinued | ORAL | N/A | Feb 19, 2019 |
| 0.175MG | tablet | Discontinued | ORAL | N/A | Feb 19, 2019 |
| 0.2MG | tablet | Discontinued | ORAL | N/A | Feb 19, 2019 |
| 0.025MG | tablet | Discontinued | ORAL | N/A | Feb 19, 2019 |
| 0.05MG | tablet | Discontinued | ORAL | N/A | Feb 19, 2019 |
| 0.3MG | tablet | Discontinued | ORAL | N/A | Feb 19, 2019 |
| 0.075MG | tablet | Discontinued | ORAL | N/A | Feb 19, 2019 |
| 0.088MG | tablet | Discontinued | ORAL | N/A | Feb 19, 2019 |
| 0.1MG | tablet | Discontinued | ORAL | N/A | Feb 19, 2019 |
| 0.112MG | tablet | Discontinued | ORAL | N/A | Feb 19, 2019 |
Manufacturing Plant Locations New
Amneal's manufacturing plants are situated in 2 countries - United States, India. Given below are the details of these plant locations as well as the firm names of Amneal as present at those locations.
| Country | City | Firm Name | ||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| United States |
| |||||||||||||||||
| India |
| |||||||||||||||||
3. ASCENT PHARMS INC
Ascent Pharmaceuticals Inc has filed for 12 different strengths of generic version for Levothyroxine Sodium. Given below are the details of the strengths of this generic introduced by Ascent Pharms Inc.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 0.075MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | tablet | Prescription | ORAL | AB4 | Jan 18, 2023 |
| 0.025MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | tablet | Prescription | ORAL | AB4 | Jan 18, 2023 |
| 0.05MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | tablet | Prescription | ORAL | AB4 | Jan 18, 2023 |
| 0.088MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | tablet | Prescription | ORAL | AB4 | Jan 18, 2023 |
| 0.1MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | tablet | Prescription | ORAL | AB4 | Jan 18, 2023 |
| 0.112MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | tablet | Prescription | ORAL | AB4 | Jan 18, 2023 |
| 0.125MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | tablet | Prescription | ORAL | AB4 | Jan 18, 2023 |
| 0.137MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | tablet | Prescription | ORAL | AB4 | Jan 18, 2023 |
| 0.15MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | tablet | Prescription | ORAL | AB4 | Jan 18, 2023 |
| 0.175MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | tablet | Prescription | ORAL | AB4 | Jan 18, 2023 |
| 0.2MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | tablet | Prescription | ORAL | AB4 | Jan 18, 2023 |
| 0.3MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | tablet | Prescription | ORAL | AB4 | Jan 18, 2023 |
4. AUROBINDO PHARMA
Aurobindo Pharma Ltd has filed for 5 different strengths of generic version for Levothyroxine Sodium. Given below are the details of the strengths of this generic introduced by Aurobindo Pharma.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 0.175MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | tablet | Prescription | ORAL | AB2 | Jul 16, 2024 |
| 0.137MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | tablet | Prescription | ORAL | AB2 | Jul 16, 2024 |
| 0.15MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | tablet | Prescription | ORAL | AB2 | Jul 16, 2024 |
| 0.2MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | tablet | Prescription | ORAL | AB2 | Jul 16, 2024 |
| 0.3MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | tablet | Prescription | ORAL | AB2 | Jul 16, 2024 |
Manufacturing Plant Locations New
Aurobindo Pharma's manufacturing plants are situated in 2 countries - India, United States. Given below are the details of these plant locations as well as the firm names of Aurobindo Pharma as present at those locations.
| Country | City | Firm Name | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| India |
| |||||||||
| United States |
| |||||||||
5. DR REDDYS
Dr Reddys Laboratories Ltd has filed for 1 generic for Levothyroxine Sodium. Given below are the details of the strengths of this generic introduced by Dr Reddys.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 100MCG/VIAL | powder | Discontinued | INTRAVENOUS | N/A | Mar 27, 2020 |
6. ENDO OPERATIONS
Endo Operations Ltd has filed for 1 generic for Levothyroxine Sodium. Given below are the details of the strengths of this generic introduced by Endo Operations.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 200MCG/VIAL | powder | Discontinued | INTRAVENOUS | N/A | Dec 7, 2015 |
7. LUPIN
Lupin Inc has filed for 12 different strengths of generic version for Levothyroxine Sodium. Given below are the details of the strengths of this generic introduced by Lupin.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 0.1MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | tablet | Prescription | ORAL | AB1,AB2,AB3 | Jan 18, 2019 |
| 0.3MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | tablet | Prescription | ORAL | AB1,AB2,AB3 | Jan 18, 2019 |
| 0.2MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | tablet | Prescription | ORAL | AB1,AB2,AB3 | Jan 18, 2019 |
| 0.175MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | tablet | Prescription | ORAL | AB1,AB2,AB3 | Jan 18, 2019 |
| 0.15MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | tablet | Prescription | ORAL | AB1,AB2,AB3 | Jan 18, 2019 |
| 0.137MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | tablet | Prescription | ORAL | AB1,AB2,AB3 | Jan 18, 2019 |
| 0.125MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | tablet | Prescription | ORAL | AB1,AB2,AB3 | Jan 18, 2019 |
| 0.025MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | tablet | Prescription | ORAL | AB1,AB2,AB3 | Jan 18, 2019 |
| 0.05MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | tablet | Prescription | ORAL | AB1,AB2,AB3 | Jan 18, 2019 |
| 0.075MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | tablet | Prescription | ORAL | AB1,AB2,AB3 | Jan 18, 2019 |
| 0.088MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | tablet | Prescription | ORAL | AB1,AB2,AB3 | Jan 18, 2019 |
| 0.112MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | tablet | Prescription | ORAL | AB1,AB2,AB3 | Jan 18, 2019 |
Manufacturing Plant Locations New
Lupin's manufacturing plants are situated in 2 countries - India, United States. Given below are the details of these plant locations as well as the firm names of Lupin as present at those locations.
| Country | City | Firm Name | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| India |
| |||||||||||||||||||||||||||||
| United States |
| |||||||||||||||||||||||||||||
8. MACLEODS PHARMS LTD
Macleods Pharmaceuticals Ltd has filed for 12 different strengths of generic version for Levothyroxine Sodium. Given below are the details of the strengths of this generic introduced by Macleods Pharms Ltd.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 0.137MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | tablet | Prescription | ORAL | AB1,AB2 | Dec 21, 2022 |
| 0.125MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | tablet | Prescription | ORAL | AB1,AB2 | Dec 21, 2022 |
| 0.112MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | tablet | Prescription | ORAL | AB1,AB2 | Dec 21, 2022 |
| 0.1MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | tablet | Prescription | ORAL | AB1,AB2 | Dec 21, 2022 |
| 0.088MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | tablet | Prescription | ORAL | AB1,AB2 | Dec 21, 2022 |
| 0.075MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | tablet | Prescription | ORAL | AB1,AB2 | Dec 21, 2022 |
| 0.05MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | tablet | Prescription | ORAL | AB1,AB2 | Dec 21, 2022 |
| 0.025MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | tablet | Prescription | ORAL | AB1,AB2 | Dec 21, 2022 |
| 0.3MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | tablet | Prescription | ORAL | AB1,AB2 | Dec 21, 2022 |
| 0.2MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | tablet | Prescription | ORAL | AB1,AB2 | Dec 21, 2022 |
| 0.15MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | tablet | Prescription | ORAL | AB1,AB2 | Dec 21, 2022 |
| 0.175MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | tablet | Prescription | ORAL | AB1,AB2 | Dec 21, 2022 |
9. MAIA PHARMS INC
Maia Pharmaceuticals Inc has filed for 3 different strengths of generic version for Levothyroxine Sodium. Given below are the details of the strengths of this generic introduced by Maia Pharms Inc.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 100MCG/VIAL | powder | Prescription | INTRAVENOUS | AP | Dec 21, 2018 |
| 200MCG/VIAL | powder | Prescription | INTRAVENOUS | AP | Dec 21, 2018 |
| 500MCG/VIAL | powder | Prescription | INTRAVENOUS | AP | Dec 21, 2018 |
10. MERCK KGAA
Merck Kgaa has filed for 11 different strengths of generic version for Levothyroxine Sodium. Given below are the details of the strengths of this generic introduced by Merck Kgaa.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 0.088MG | tablet | Discontinued | ORAL | N/A | Jun 16, 2005 |
| 0.112MG | tablet | Discontinued | ORAL | N/A | Jun 16, 2005 |
| 0.1MG | tablet | Discontinued | ORAL | N/A | Jun 16, 2005 |
| 0.125MG | tablet | Discontinued | ORAL | N/A | Jun 16, 2005 |
| 0.05MG | tablet | Discontinued | ORAL | N/A | Jun 16, 2005 |
| 0.3MG | tablet | Discontinued | ORAL | N/A | Jun 16, 2005 |
| 0.2MG | tablet | Discontinued | ORAL | N/A | Jun 16, 2005 |
| 0.075MG | tablet | Discontinued | ORAL | N/A | Jun 16, 2005 |
| 0.175MG | tablet | Discontinued | ORAL | N/A | Jun 16, 2005 |
| 0.15MG | tablet | Discontinued | ORAL | N/A | Jun 16, 2005 |
| 0.025MG | tablet | Discontinued | ORAL | N/A | Jun 16, 2005 |
Manufacturing Plant Locations New
Merck Kgaa's manufacturing plants are situated in 1 country - Germany. Given below are the details of these plant locations as well as the firm names of Merck Kgaa as present at those locations.
| Country | City | Firm Name | ||
|---|---|---|---|---|
| Germany |
| |||
11. MYLAN
Mylan Pharmaceuticals Inc has filed for 12 different strengths of generic version for Levothyroxine Sodium. Given below are the details of the strengths of this generic introduced by Mylan.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 0.1MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | tablet | Prescription | ORAL | AB1,AB2,AB3,AB4 | Jun 5, 2002 |
| 0.112MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | tablet | Prescription | ORAL | AB1,AB2,AB3,AB4 | Jun 5, 2002 |
| 0.3MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium
(reference standard) | tablet | Prescription | ORAL | AB1,AB2,AB3,AB4 | Jun 5, 2002 |
| 0.15MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | tablet | Prescription | ORAL | AB1,AB2,AB3,AB4 | Jun 5, 2002 |
| 0.175MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | tablet | Prescription | ORAL | AB1,AB2,AB3,AB4 | Jun 5, 2002 |
| 0.2MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | tablet | Prescription | ORAL | AB1,AB2,AB3,AB4 | Jun 5, 2002 |
| 0.025MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | tablet | Prescription | ORAL | AB1,AB2,AB3,AB4 | Jun 5, 2002 |
| 0.05MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | tablet | Prescription | ORAL | AB1,AB2,AB3,AB4 | Jun 5, 2002 |
| 0.075MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | tablet | Prescription | ORAL | AB1,AB2,AB3,AB4 | Jun 5, 2002 |
| 0.088MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | tablet | Prescription | ORAL | AB1,AB2,AB3,AB4 | Jun 5, 2002 |
| 0.125MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | tablet | Prescription | ORAL | AB1,AB2,AB3,AB4 | Jun 5, 2002 |
| 0.137MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | tablet | Prescription | ORAL | AB1,AB2,AB3,AB4 | Dec 13, 2006 |
Manufacturing Plant Locations New
Mylan's manufacturing plants are situated in 4 countries - United States, India, Canada, Ireland. Given below are the details of these plant locations as well as the firm names of Mylan as present at those locations.
| Country | City | Firm Name | ||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| United States |
| |||||||||||||||||
| India |
| |||||||||||||||||
| Canada |
| |||||||||||||||||
| Ireland |
| |||||||||||||||||
12. PIRAMAL CRITICAL
Piramal Critical Care Ltd has filed for 2 different strengths of generic version for Levothyroxine Sodium. Given below are the details of the strengths of this generic introduced by Piramal Critical.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 100MCG/VIAL | powder | Prescription | INTRAVENOUS | AP | Jun 29, 2016 |
| 500MCG/VIAL | powder | Prescription | INTRAVENOUS | AP | Jun 29, 2016 |
Manufacturing Plant Locations New
Piramal Critical's manufacturing plants are situated in 1 country - United States. Given below are the details of these plant locations as well as the firm names of Piramal Critical as present at those locations.
| Country | City | Firm Name | ||
|---|---|---|---|---|
| United States |
| |||
13. TEVA PHARMS USA INC
Teva Pharmaceuticals Usa Inc has filed for 9 different strengths of generic version for Levothyroxine Sodium. Given below are the details of the strengths of this generic introduced by Teva Pharms Usa Inc.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 0.15MG | capsule | Discontinued | ORAL | N/A | Oct 28, 2020 |
| 0.075MG | capsule | Discontinued | ORAL | N/A | Oct 28, 2020 |
| 0.088MG | capsule | Discontinued | ORAL | N/A | Jan 6, 2021 |
| 0.1MG | capsule | Discontinued | ORAL | N/A | Jan 6, 2021 |
| 0.125MG | capsule | Discontinued | ORAL | N/A | Jan 6, 2021 |
| 0.112MG | capsule | Discontinued | ORAL | N/A | Apr 16, 2021 |
| 0.2MG | capsule | Discontinued | ORAL | N/A | Nov 9, 2022 |
| 0.175MG | capsule | Discontinued | ORAL | N/A | May 2, 2023 |
| 0.137MG | capsule | Discontinued | ORAL | N/A | May 2, 2023 |
14. WATSON LABS TEVA
Watson Laboratories Inc An Indirect Wholly Owned Sub Of Teva Pharmaceuticals Usa Inc has filed for 12 different strengths of generic version for Levothyroxine Sodium. Given below are the details of the strengths of this generic introduced by Watson Labs Teva.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 0.1MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | tablet | Prescription | ORAL | AB1,AB2,AB3,AB4 | May 10, 2022 |
| 0.025MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | tablet | Prescription | ORAL | AB1,AB2,AB3,AB4 | May 10, 2022 |
| 0.05MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | tablet | Prescription | ORAL | AB1,AB2,AB3,AB4 | May 10, 2022 |
| 0.075MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | tablet | Prescription | ORAL | AB1,AB2,AB3,AB4 | May 10, 2022 |
| 0.088MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | tablet | Prescription | ORAL | AB1,AB2,AB3,AB4 | May 10, 2022 |
| 0.112MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | tablet | Prescription | ORAL | AB1,AB2,AB3,AB4 | May 10, 2022 |
| 0.125MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | tablet | Prescription | ORAL | AB1,AB2,AB3,AB4 | May 10, 2022 |
| 0.137MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | tablet | Prescription | ORAL | AB1,AB2,AB3,AB4 | May 10, 2022 |
| 0.15MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | tablet | Prescription | ORAL | AB1,AB2,AB3,AB4 | May 10, 2022 |
| 0.175MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | tablet | Prescription | ORAL | AB1,AB2,AB3,AB4 | May 10, 2022 |
| 0.2MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | tablet | Prescription | ORAL | AB1,AB2,AB3,AB4 | May 10, 2022 |
| 0.3MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium | tablet | Prescription | ORAL | AB1,AB2,AB3,AB4 | May 10, 2022 |
15. XIROMED
Xiromed Pharma Espana Sl has filed for 1 generic for Levothyroxine Sodium. Given below are the details of the strengths of this generic introduced by Xiromed.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 100MCG/VIAL | powder | Prescription | INTRAVENOUS | AP | Nov 29, 2024 |
Manufacturing Plant Locations New
Xiromed's manufacturing plants are situated in 1 country - United States. Given below are the details of these plant locations as well as the firm names of Xiromed as present at those locations.
| Country | City | Firm Name | ||
|---|---|---|---|---|
| United States |
| |||
16. ZYDUS PHARMS
Zydus Pharmaceuticals Usa Inc has filed for 3 different strengths of generic version for Levothyroxine Sodium. Given below are the details of the strengths of this generic introduced by Zydus Pharms.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 500MCG/VIAL | powder | Prescription | INTRAVENOUS | AP | Mar 24, 2023 |
| 100MCG/VIAL | powder | Prescription | INTRAVENOUS | AP | Mar 24, 2023 |
| 200MCG/VIAL | powder | Prescription | INTRAVENOUS | AP | Mar 24, 2023 |